articleTop 1% cited

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

The Lancet Oncology · 2006 · Vol. 7(5) · pp. 379–391

Michael Pfreundschuh✉(Saarland University)Lorenz Trümper(University of Göttingen)Anders Österborg(Karolinska University Hospital)Ruth Pettengell(St George's Hospital)Marek Trněný(Charles University)Kevin Imrie(Sunnybrook Health Science Centre)Dávid Ma(St Vincent's Hospital Sydney)Devinder Gill(Princess Alexandra Hospital)Jan WalewskiPier Luigi Zinzani(Istituto Oncologico Romagnolo)Rolf A. Stahel(University Hospital of Zurich)Stein Kvaløy(Norwegian Cancer Society)Ofer Shpilberg(Soroka Medical Center)Ulrich Jaeger(Vienna General Hospital)Mads Hansen(Rigshospitalet)Tuula Lehtinen(Savonlinna Central Hospital)Armando López‐GuillermoClaudia Corrado(Fundación para la Investigación, Docencia y Prevención del Cáncer)Adriana Scheliga(Instituto Nacional do Câncer)Nöel Milpied(Nantes Université)Myriam Mendila(Roche (Switzerland))Michelle Rashford(Roche (Switzerland))Evelyn KuhntMarkus Loeffler(Leipzig University)

View via DOI Publisher page

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Acute Lymphoblastic Leukemia researchMedicineRituximabCHOPInternal medicineVincristineInternational Prognostic IndexChemotherapyClinical endpointDiffuse large B-cell lymphomaLymphoma

MeSH terms

RituximabAdolescentAdultAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansLymphoma, Non-HodgkinMiddle AgedPrednisonePrognosisVincristineSurvival Rate

Citations

2,073

FWCI

74.02

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy